K2HV converts $2.5M loan principal into 2.85M NMRA shares at $0.8774/share

Neumora Therapeutics, Inc.

K2 HealthVentures converted $2.5M of term-loan principal into 2,849,327 common shares of NMRA at $0.8774/share.
Conversion was exercised under loan agreement dated May 9, 2025, as amended November 4, 2025.
Shares were issued in reliance on Section 4(a)(2) exemption from registration.
Total conversion right under loan agreement remains up to $12.5M; $10M principal remains convertible.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Neumora Therapeutics, Inc. issued 2,849,327 shares of common stock of common stock to K2 HealthVentures Equity Trust LLC for conversion of $2.5 million of principal amount at $0.8774 per share.

Security: common stock
Shares: 2,849,327 shares of common stock
Purchaser: K2 HealthVentures Equity Trust LLC
Consideration: conversion of $2.5 million of principal amount at $0.8774 per share

Exact text from the filing

of the term loans into shares of common stock of the Company. On November 17, 2025, the Company received a conversion notice from K2HV, pursuant to which K2HV elected to convert $2.5 million of principal amount of the term loan into common stock of the Company, at a conversion price of $0.8774 per share, in accordance with the Loan Agreement. On November 20, 2025,

View on SEC.gov

Browse all equity issuances →

Neumora Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-291352

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.